Last reviewed · How we verify
NCT06140537
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
Phase 4 trial testing Dapagliflozin 10mg Tab in Kidney Transplant; Complications in 80 participants. Currently enrolling.
31 October 2028
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 February 2024 |
| Primary completion | 31 October 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dapagliflozin 10mg Tab — full drug profile →
- Placebo
Conditions studied
- Kidney Transplant; Complications — all drugs for Kidney Transplant; Complications →
- Vascular Diseases — all drugs for Vascular Diseases →
- Diabetes — all drugs for Diabetes →
Sponsor
University of Colorado, Denver
Who can join
Adults 18 to 80, any sex, with Kidney Transplant; Complications or Vascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Long-term allograft function in kidney transplant recipients (KTRs) remain suboptimal, and graft failure causes significant morbidity and mortality, with cardiovascular disease being the leading cause of death in KTRs and the most common cause of death with a functioning graft. Sodium-glucose cotransporter 2 (SGLT2) inhibitors safely lower cardiovascular and kidney disease risk in the non-transplant population, yet data in KTRs are lacking. This clinical trial seeks to establish the efficacy and safety of dapagliflozin, a SGLT2 inhibitor, for improving cardiovascular and kidney graft function in adult KTRs with type 2 diabetes and post-transplant diabetes, and to leverage innovate translational methods to define the underlying mechanisms of action.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cardiac impact of dapagliflozin in advanced chronic kidney disease: rationale and design of the Renal Lifecycle Trial cardiac imaging sub-studies.
Karsten M, Badve SV, Gansevoort RT, Berger SP, et al · · 2026 · PMID 41551843 · DOI 10.1093/ckj/sfaf376
Verify or expand the search:
- PubMed search for NCT06140537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dapagliflozin 10mg Tab
Trials testing the same drug.
- NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
- NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
- NCT06427226 — Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity · Phase 2 · recruiting
- NCT06373523 — MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin · EARLY_PHASE1 · not yet recruiting
- NCT06434025 — IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency · Phase 3 · not yet recruiting
Other recruiting trials for Kidney Transplant; Complications
Currently open trials in the same condition.
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
- NCT06958796 — Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) · Phase 4 · recruiting
- NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
- NCT07033858 — Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation · NA · recruiting
- NCT05782543 — Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion · NA · recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06140537 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06140537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing